Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Oratie Michiel van de Sande over vooruitgang sarcoomzorg
nov 2021 | Bot en wekedelentumoren